Eurotimes Articles

  • 04/13/2015 - 12:26 MARKETING AUTHORISATION April, 2015, Features Santen Pharmaceutical has announced that the European Medicines Agency (EMA) has accepted the company’s Marketing Authorisation Application (MAA) filing for the use of intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of noninfectious uveitis (NIU) of the posterior segment.
  • 04/02/2015 - 11:26 schemes reduce risk April, 2015, Ocular Programmes that provide protective eyewear to agricultural workers in developing countries can significantly reduce the risk of eye injuries
  • 04/02/2015 - 11:16 PROFESSOR DAVID SPALTON IS ESCRS PRESIDENT-ELECT April, 2015, Features Prof Spalton shares his views on the past, present and future of ophthalmology
  • 04/02/2015 - 11:13 THERAPYFOR DME April, 2015, Retina The top three anti-VEGF agents – aflibercept (Eylea, Regeneron), bevacizumab (Avastin, Genentech/Novartis) and ranibizumab (Lucentis, Genentech/Novartis) – all appear to provide substantial clinical benefit for patients with diabetic macular oedema (DME), with aflibercept providing the greatest visual improvements.
  • 04/02/2015 - 11:04 HERO HELMET April, 2015, Features, Top Story Leigh Spielberg explains how it sometimes pays off to invest in the gadget yourself
  • 04/02/2015 - 10:53 DIVIDE AND CONQUER April, 2015, Features
  • 04/02/2015 - 10:50 19TH ESCRS WINTER MEETING ISTANBUL April, 2015, Features Delegates from 88 countries around the world defied snow to attend the 19TH ESCRS Winter Meeting in Istanbul, Turkey
  • 04/02/2015 - 10:48 IMPROVING THE OOKP Cornea, April, 2015 The osteo-odonto-keratoprosthesis (OOKP) is associated with the greatest long-term anatomical and functional success among the different approaches available. However, like all keratoprostheses, the OOKP has limitations
  • 04/02/2015 - 10:44 IMPROVING THE OOKP
  • 04/02/2015 - 10:40 TARGETED APPROACH April, 2015, Retina Early diagnosis, referral to a uveitis specialist and therapeutic aggressiveness employing a ‘stepladder’ approach that is both steroid-sparing and individually tailored offers the best approach to successfully treating uveitis.

Popular Items